Can brexpiprazole (Rexulti) be combined with paroxetine (Paxil)?

Rexulti and Paxil Combination

Yes, brexpiprazole (Rexulti) can be safely combined with paroxetine (Paxil), but the Rexulti dose must be reduced to half of the usual target dose due to a significant pharmacokinetic drug interaction. 1

Dosing Adjustment Required

Paroxetine is a strong CYP2D6 inhibitor that increases brexpiprazole exposure, necessitating dose reduction of Rexulti to prevent adverse effects. 1

• When combining Rexulti with paroxetine (a strong CYP2D6 inhibitor), reduce the Rexulti dosage to half of the usual target dose 1
• For major depressive disorder (MDD) specifically, the FDA label notes that dosage adjustment may not be required because clinical trials examining adjunctive Rexulti in MDD did not adjust for strong CYP2D6 inhibitors like paroxetine and fluoxetine, meaning CYP considerations are already factored into general dosing recommendations 1
• This creates a practical advantage: in MDD patients, Rexulti can be administered at standard doses (1-3 mg/day) even when combined with paroxetine 1

Clinical Evidence Supporting Combination

The combination of brexpiprazole with SSRIs (including paroxetine) demonstrates synergistic antidepressant effects superior to either medication alone. 2, 3

• Preclinical studies show that brexpiprazole combined with SSRIs (including paroxetine) produces significantly greater reduction in depression-like behavior than vehicle or single treatments, with confirmed statistical interaction effects (p = 0.0411) 2
• A phase 3 randomized trial demonstrated that brexpiprazole combined with sertraline (another SSRI) produced statistically significant improvement in PTSD symptoms compared to sertraline alone, with LS mean difference of -5.59 (95% CI, -8.79 to -2.38; P < .001) 3
• Pooled analysis of six randomized studies showed adjunctive brexpiprazole with antidepressants improved functioning in MDD patients with inadequate antidepressant response (LS mean difference -0.40; 95% CI: -0.56, -0.23; P < .0001) 4

Safety Considerations

Monitor for serotonin syndrome when combining any two serotonergic medications, though risk is lower with non-MAOI combinations. 5

Serotonin Syndrome Risk

• Combining serotonergic drugs like paroxetine (SSRI) with brexpiprazole requires caution, though the risk is substantially lower than with MAOIs 5
• Start at low doses, increase slowly, and monitor for symptoms especially in the first 24-48 hours after dosage changes 5
• Symptoms include mental status changes (confusion, agitation, anxiety), neuromuscular hyperactivity (tremors, clonus, hyperreflexia), and autonomic hyperactivity (hypertension, tachycardia, diaphoresis) 5
• Advanced symptoms can include fever, seizures, arrhythmias, and unconsciousness requiring hospitalization 5

Paroxetine-Specific Concerns

• Paroxetine has been associated with increased risk of suicidal thinking or behavior compared to other SSRIs 5
• Paroxetine is associated with discontinuation syndrome more than other SSRIs due to its shorter half-life 5
• Paroxetine interacts with drugs metabolized by CYP2D6 5
• In older adults, paroxetine should generally be avoided due to higher rates of adverse effects; other SSRIs like escitalopram or sertraline are preferred 5

Common Adverse Effects of Combination

• Treatment-emergent adverse events with brexpiprazole + SSRI combinations (≥5% incidence) include nausea (12.2%), fatigue (6.8%), weight increase (5.9%), and somnolence (5.4%) 3
• Discontinuation rates due to adverse events were actually lower with brexpiprazole + sertraline (3.9%) compared to sertraline alone (10.2%) in one large trial 3
• The safety profile is consistent with brexpiprazole in approved indications 6, 3

Mechanism of Synergy

The combination enhances dopamine neuronal activity through AMPA receptor modulation while normalizing serotonin and norepinephrine neuron firing. 7

• Brexpiprazole combined with serotonergic agents more than doubles the population activity of dopamine neurons through AMPA receptor mechanisms 7
• This occurs early during administration (within 2 days) and results in overall increases in both serotonin and norepinephrine transmission in the hippocampus 7
• The mechanism suggests this strategy could provide rapid-acting antidepressant effects 7

Clinical Application Algorithm

1. For MDD patients: Initiate standard Rexulti dosing (1-3 mg/day) with paroxetine without dose adjustment, as clinical trials support this approach 1

2. For schizophrenia or other indications: Reduce Rexulti to half the usual target dose when combining with paroxetine 1

3. Monitor closely during initiation: Watch for serotonin syndrome symptoms in the first 24-48 hours after starting combination or dose changes 5

4. Allow adequate trial duration: Brexpiprazole may take 6-12 weeks to demonstrate full efficacy when used for agitation or other indications 8

5. Assess for drug-drug interactions: Be aware that paroxetine's CYP2D6 inhibition affects multiple medications beyond brexpiprazole 5